Cord Blood CAR-NK Cells: Favorable Initial Efficacy and Toxicity but Durability of Clinical Responses Not Yet Clear

Cancer Cell. 2020 Apr 13;37(4):426-427. doi: 10.1016/j.ccell.2020.03.018.

Abstract

Chimeric antigen receptor (CAR)-T cell immunotherapy is highly effective against B lineage cancers but at the expense of potentially serious toxicity such as cytokine release syndrome (CRS) and neurotoxicity. Recent work provided clinical evidence that allogeneic, cord blood CAR-NK cells induce high rates of non-durable clinical responses without CRS or neurotoxicity.

Publication types

  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Cytokines
  • Fetal Blood
  • Immunotherapy, Adoptive*
  • Killer Cells, Natural
  • Receptors, Antigen, T-Cell
  • Receptors, Chimeric Antigen* / genetics

Substances

  • Cytokines
  • Receptors, Antigen, T-Cell
  • Receptors, Chimeric Antigen